Encorafenib
- Generic Name
- Encorafenib
- Brand Names
- Braftovi
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27ClFN7O4S
- CAS Number
- 1269440-17-6
- Unique Ingredient Identifier
- 8L7891MRB6
- Background
Encorafenib, also known as BRAFTOVI, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most fr...
- Indication
Encorafenib is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation and metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. It is also indicated in combination with cetuximab for the treatment of adult patients with metastatic colorecta...
- Associated Conditions
- Metastatic Colorectal Cancer (CRC), Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Unresectable Melanoma
- Associated Therapies
- -
Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 16
- Registration Number
- NCT06578559
- Locations
- 🇮🇹
Pia Fondazione di Culto e di Religione Cardinale G. Panico, Tricase, LE, Italy
🇮🇹Istituto Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" Irccs Irst, Meldola, FC, Italy
🇮🇹Fondazione Casa Sollievo Della Sofferenza - Irccs, San Giovanni Rotondo, FG, Italy
Combination Therapy for BRAF-V600E Metastatic CRCm
- Conditions
- Interventions
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Vall d'Hebron Institute of Oncology
- Target Recruit Count
- 94
- Registration Number
- NCT06411600
- Locations
- 🇪🇸
Vall d'Hebron Hospital, Barcelona, Spain
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 33
- Registration Number
- NCT06194929
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT06102902
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT05985954
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 150
- Registration Number
- NCT05926960
- Locations
- 🇮🇹
Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
🇮🇹Istituto Europeo di Oncologia IRCCS, Milano, Italy
🇸🇰Nemocnica Poprad, a.s., Poprad, Slovakia
ZN-c3 in Adult Participants with Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2024-11-26
- Target Recruit Count
- 82
- Registration Number
- NCT05743036
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Alliance for Multispecialty Research, LLC, Merriam, Kansas, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05725200
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 394
- Registration Number
- NCT05710406
- Locations
- 🇺🇸
The Queen's Medical Center - West Oahu, 'Ewa Beach, Hawaii, United States
🇺🇸Rush - Copley Medical Center, Aurora, Illinois, United States
🇺🇸Rush-Copley Healthcare Center, Yorkville, Illinois, United States
Personalized Medicine for Advanced Biliary Cancer Patients
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 800
- Registration Number
- NCT05615818
- Locations
- 🇧🇪
Universitair Ziekenhuis Leuven, Leuven, Belgium
🇫🇷CHU Amiens Picardie, Amiens, France
🇫🇷CHU d'Angers, Angers, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.